



- (51) **International Patent Classification:**
C07K 7/62 (2006.01) *A61K 38/12* (2006.01)
- (21) **International Application Number:**
PCT/GB2012/052844
- (22) **International Filing Date:**
16 November 2012 (16.11.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/561,361 18 November 2011 (18.11.2011) US
- (71) **Applicants:** **NOVACTA BIOSYSTEMS LIMITED** [GB/GB]; Biopark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **CANTAB ANTI-INFECTIVES LIMITED** [GB/GB]; 4th Floor, Reading Bridge House, George Street, Reading, Berkshire RG1 8LS (GB).
- (72) **Inventors:** **SAADI, Mona**; Cantab Biopharmaceuticals Limited, Biopark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **DUPERCHY, Esther**; Cantab Biopharmaceuticals Limited, Biopark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **BROWN, Pamela**; Cantab Biopharmaceuticals Limited, Biopark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **DAWSON, Michael John**; Cantab Biopharmaceut-

icals Limited, Biopark Hertfordshire, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB). **WADMAN, Sjoerd Nicolaas**; Rebgrasse 4, 79618 Rheinfelden (DE).

- (74) **Agents:** **WILLS, Jonathan** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London, Greater London EC2V 8AS (GB).



(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** POLYMYXIN DERIVATIVES

Figure 1



(I)

(57) **Abstract:** Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is -NHC(O)-, -C(O)-, -OC(O)-, -CH₂- or -SO₂-; R⁵ represents C₁₀₋₁₂ alkyl(C₄₋₆ heterocyclyl), or C₂₋₁₂, -> alkyl or C₀₋₁₂ alkyl(C₃₋₈ cycloalkyl), and the alkyl or cycloalkyl bears one, two or three hydroxyl groups, or a -NF⁶R⁷ group, or one -NR⁶R⁷ group and one or two hydroxyl groups; and R¹ to R⁴ and R⁶ to R⁸ are as defined in the description.



Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*